Stock LLM Wiki

報告_MS_貿聯3665_20260902

更新 2026-09-05

PDF 原檔:報告_MS_貿聯3665_20260902_original.pdf

原始內容

M September 2, 2026 05:02 AM GMT

Read-across from Credo's FY1Q27 Results

We see positive implications for Bizlink from Credo's comments on expanding AEC and emerging ALC opportunities.

FY1Q27 (ended July 2026) results:

  • Credo (CRDO.US, not covered) reported revenue of US$479mn (+10% QoQ/ +115% YoY), roughly in line with the consensus of US$474mn and guidance of US$465-475mn.
  • Non-GAAP GM was 68% (-0.3ppt QoQ) in line with consensus at 68% and guidance at 67-69%.
  • Non-GAAP NP was US$236mn (+4% QoQ/+140% YoY), roughly in line with consensus at US$232mn.
  • Four customers each contributed more than 10% of Credo's revenue in FY1Q27, i.e., 33%, 28%, 13% and 10%, respectively.

FY2Q27 and FY27 outlook:

  • FY2Q27 revenue is guided to be US$525-535mn (+11% QoQ/+98% YoY at the midpoint, largely in line with consensus of US$526mn), non-GAAP GM of 6769% (vs. consensus at 67.5%) and opex of US$100-105mn.
  • For FY27, Credo now expects total revenue to grow >85% YoY (vs. consensus at ~86% YoY), with an inflection in 2H mainly from optical revenue (>US$600mn for FY27 from Zero-Flap Optics, silicon photonics PICs and optical DSPs, with each to contribute >US$100mn).
  • Credo expects its FY27 GM to stay flat YoY, while operating expenses might increase by ~55% YoY.
  • 1.6T AEC might start to emerge from 2HFY27.
  • ALCs and OmniConnect gearboxes remain on track for initial revenue from FY28, management believes both are multi-billion dollar opportunities for Credo.
  • It also sees increasing customer activity on NPO for scale up network, with
  • confirmed PIC design wins for ramp in FY28.
  • We see positive implications from Credo's comments on the AEC's spec upgrade and its penetration into more hyperscalers and neoclouds, as well as the reiterated timing of ALC ramp in FY28.
  • We stay constructive on Bizlink for its multiple drivers in the AI deployment theme, including data/power interconnects and semi cap equipment.

Morgan Stanley Taiwan Limited+

Derrick Yang

Equity Analyst

Derrick.Yang@morganstanley.com

Vivi Huang

Research Associate

Vivi.Huang@morganstanley.com

Morgan Stanley Asia Limited+

Andy Meng, CFA

Equity Analyst

Andy.Meng@morganstanley.com

Greater China Technology Hardware | Taiwan

Stock Rating Stock Rating Stock Rating Stock Rating Overweight
Industry View Industry View Industry View Industry View In-Line
Price target Price target Price target Price target NT$3,665.00
Up/downside to price target (%) Up/downside to price target (%) Up/downside to price target (%) Up/downside to price target (%) 58
Shr price, close (Sep 1, 2026) Shr price, close (Sep 1, 2026) Shr price, close (Sep 1, 2026) NT$2,315.00 NT$2,315.00
52-Week Range 52-Week Range 52-Week Range NT$3,010.00-946.00 NT$3,010.00-946.00
Sh out, dil, curr (mn) Sh out, dil, curr (mn) Sh out, dil, curr (mn) 193 193
Mkt cap, curr (mn) Mkt cap, curr (mn) Mkt cap, curr (mn) NT$447,642 NT$447,642
EV, curr (mn) EV, curr (mn) EV, curr (mn) NT$453,219 NT$453,219
Avg daily trading value (mn) Avg daily trading value (mn) Avg daily trading value (mn) NT$6,299 NT$6,299
Fiscal Year Ending 12/25 12/26e 12/27e 12/28e
EPS (NT$)** 46.57 69.77 120.77 143.77
Prior EPS (NT$)** - - - -
EPS (NT$)§ 47.71 68.21 115.41 151.04
Revenue, net (NT$ mn) 71,247 101,953 151,516 174,996
EBITDA (NT$ mn) 15,154 21,153 34,384 41,510
ModelWare net inc (NT 9,005 13,491 23,353 27,800
$ mn)
P/E 32.6 33.2 19.2 16.1
P/BV 6.4 8.0 6.0 4.7
RNOA (%) 24.2 26.2 39.8 41.7
ROE (%) 24.9 28.9 40.8 36.5
EV/EBITDA 20.1 21.2 12.8 10.2
Div yld (%) 0.8 0.6 1.0 1.7
FCF yld ratio (%)** (0.8) 1.6 3.2 5.4
Leverage (EOP) (%) (0.9) (8.3) (19.1) (32.5)

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework

** = Based on consensus methodology

§ = Consensus data is provided by Refinitiv Estimates

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.